We found that, compared with the untreated group, mice in the anti–PD-1 or TDO2i group showed reduced tumor volumes, and the combination of TDO2i plus anti–PD-1 resulted in the greatest tumor reduction (Figure 8, A and B), suggesting that the combination therapy could effectively inhibit tumor progression. Here, PDCD1 is linked to neoplasm.